{
"@context": "https://schema.org",
"@graph": [
{
"@type": "WebPage",
"@id": "https://www.fortrea.com/insights/driving-biotechs-early-phase-development-competitive-rare-disease-clinical-trial-landscape#webpage",
"url": "https://www.fortrea.com/insights/driving-biotechs-early-phase-development-competitive-rare-disease-clinical-trial-landscape",
"name": "Driving a biotech’s early phase development in a competitive rare disease clinical trial landscape",
"description": "Explore this Fortrea Case Study highlighting how strategic planning, operational expertise, and collaborative execution supported a biotech company's early phase rare disease clinical development program within a highly competitive clinical trial environment. Rare disease studies often face challenges related to limited patient populations, competition for experienced investigative sites, complex recruitment requirements, and evolving development timelines. This case study demonstrates how Fortrea partnered with the sponsor to develop and execute a tailored clinical strategy that addressed feasibility considerations, patient recruitment needs, site engagement, and study execution requirements during the critical early stages of development. The resource highlights the importance of proactive planning, stakeholder collaboration, operational flexibility, and rare disease expertise in helping emerging biotech organizations navigate competitive clinical trial landscapes while maintaining development momentum. Through strategic clinical development support, recruitment planning, and effective site partnerships, Fortrea helped position the program for successful progression while supporting key early phase development objectives and broader rare disease drug development goals"
},
{
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "Home",
"item": "https://www.fortrea.com"
},
{
"@type": "ListItem",
"position": 2,
"name": "Insights",
"item": "https://www.fortrea.com/insights/"
},
{
"@type": "ListItem",
"position": 3,
"name": "Driving a biotech’s early phase development in a competitive rare disease clinical trial landscape",
"item": "https://www.fortrea.com/insights/driving-biotechs-early-phase-development-competitive-rare-disease-clinical-trial-landscape"
}
]
},
{
"@type": "Organization",
"@id": "https://www.fortrea.com/#organization",
"name": "Fortrea",
"url": "https://www.fortrea.com",
"description": "Fortrea is a global contract research organization built on more than 30 years of experience and one of the earliest CRO legacies in the industry—as Covance, evolving within Labcorp, and now operating as Fortrea. With deep expertise across Phase I–IV clinical trials, Fortrea advances clinical research through a patient-centric approach that prioritizes meaningful outcomes, stronger site–CRO relationships, and operational excellence. Fortrea partners with biopharmaceutical, biotech, and medical device companies to advance therapies through every stage of clinical development. This commitment is further reinforced by the launch of Fortrea Intelligent Technology, enabling smarter, more connected, and data-driven clinical development. Through Fortrea Intelligent Technology, the organization is advancing data-driven, technology-enabled clinical development to improve speed, quality, and patient outcomes. It is shaped by experience, innovation, and a commitment to raising standards in clinical research—focused on accelerating development and helping bring life-changing treatments to patients around the world.",
"logo": "https://www.fortrea.com/sites/default/files/2025-05/fortrea-logo-without-background.png",
"sameAs": [
"https://www.linkedin.com/company/fortrea",
"https://www.threads.net/@fortreacro",
"https://twitter.com/fortrea",
"https://www.youtube.com/@Fortrea/",
"https://www.facebook.com/Fortrea-104143099267108",
"https://www.instagram.com/fortreacro"
]
},
{
"@type": "Article",
"@id": "https://www.fortrea.com/insights/driving-biotechs-early-phase-development-competitive-rare-disease-clinical-trial-landscape#casestudy",
"mainEntityOfPage": {
"@id": "https://www.fortrea.com/insights/driving-biotechs-early-phase-development-competitive-rare-disease-clinical-trial-landscape#webpage"
},
"headline": "Driving Early Phase Rare Disease Clinical Development in a Competitive Trial Landscape | Fortrea Case Study",
"description": "Explore this Fortrea Case Study highlighting how strategic planning, operational expertise, and collaborative execution supported a biotech company's early phase rare disease clinical development program within a highly competitive clinical trial environment. Rare disease studies often face challenges related to limited patient populations, competition for experienced investigative sites, complex recruitment requirements, and evolving development timelines. This case study demonstrates how Fortrea partnered with the sponsor to develop and execute a tailored clinical strategy that addressed feasibility considerations, patient recruitment needs, site engagement, and study execution requirements during the critical early stages of development. The resource highlights the importance of proactive planning, stakeholder collaboration, operational flexibility, and rare disease expertise in helping emerging biotech organizations navigate competitive clinical trial landscapes while maintaining development momentum. Through strategic clinical development support, recruitment planning, and effective site partnerships, Fortrea helped position the program for successful progression while supporting key early phase development objectives and broader rare disease drug development goals",
"genre": "Case Study",
"image": {
"@type": "ImageObject",
"url": "https://www.fortrea.com/sites/default/files/2025-05/fortrea-logo-without-background.png"
},
"author": {
"@type": "Organization",
"name": "Fortrea",
"url": "https://www.fortrea.com/"
},
"publisher": {
"@id": "https://www.fortrea.com/#organization"
},
"datePublished": "2026-05-11",
"dateModified": "2026-05-11",
"encoding": {
"@type": "MediaObject",
"contentUrl": "https://www.fortrea.com/sites/default/files/2026-05/early-phase-biotech-rare-disease-clinical-trial-case-study.pdf",
"encodingFormat": "application/pdf"
}
}
]
}